Neil W Gibson
Overview
Explore the profile of Neil W Gibson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
1448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Mulvihill M, Ji Q, Coate H, Cooke A, Dong H, Feng L, et al.
Bioorg Med Chem
. 2007 Nov;
16(3):1359-75.
PMID: 17983756
A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR (IGF-1R) inhibitors--most notably, cis-3-(3-azetidin-1-ylmethylcyclobutyl)-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-8-ylamine (AQIP)--is described. Synthetic details, structure-activity relationships, and in vitro biological activity are reported for the series. Key in...
12.
Ji Q, Mulvihill M, Rosenfeld-Franklin M, Cooke A, Feng L, Mak G, et al.
Mol Cancer Ther
. 2007 Aug;
6(8):2158-67.
PMID: 17671083
Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and IGF-II, are up-regulated in a variety of human cancers. In tumors, such as colorectal, non-small cell lung, ovarian, and pediatric...
13.
Wang J, Kuropatwinski K, Hauser J, Rossi M, Zhou Y, Conway A, et al.
Mol Cancer Ther
. 2007 Mar;
6(3):1143-50.
PMID: 17363507
PIK3CA, encoding the p110alpha catalytic subunit of phosphatidylinositol 3-kinase (PI3K), is mutated in a variety of human cancers. We screened the colon cancer cell lines previously established in our laboratory...
14.
Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, et al.
Mol Cancer Ther
. 2007 Feb;
6(2):532-41.
PMID: 17308052
Overexpression and enhanced activation of the epidermal growth factor receptor (EGFR) is frequently observed in human carcinomas. Inhibitors of EGFR signaling have shown clinical utility; however, understanding response at the...
15.
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley J, et al.
Mol Cancer Ther
. 2006 Nov;
5(11):2676-84.
PMID: 17121914
The receptor for epidermal growth factor (EGFR) is overexpressed in many cancers. One important signaling pathway regulated by EGFR is the phosphatidylinositol 3'-kinase (PI3K)-phosphoinositide-dependent kinase 1-Akt pathway. Activation of Akt...
16.
Buck E, Eyzaguirre A, Haley J, Gibson N, Cagnoni P, Iwata K
Mol Cancer Ther
. 2006 Aug;
5(8):2051-9.
PMID: 16928826
Signaling through the receptor for epidermal growth factor receptor (EGFR) is frequently deregulated in solid tumors. Erlotinib (Tarceva, OSI-774, OSI Pharmaceuticals, Inc., Melville, NY) is a low molecular weight, orally...
17.
Mulvihill M, Kan J, Cooke A, Bhagwat S, Beck P, Bittner M, et al.
Bioorg Med Chem Lett
. 2006 Mar;
16(10):2729-33.
PMID: 16504501
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase...
18.
Garton A, Crew A, Franklin M, Cooke A, Wynne G, Castaldo L, et al.
Cancer Res
. 2006 Jan;
66(2):1015-24.
PMID: 16424037
OSI-930 is a novel inhibitor of the receptor tyrosine kinases Kit and kinase insert domain receptor (KDR), which is currently being evaluated in clinical studies. OSI-930 selectively inhibits Kit and...